LIFE IS HARD
YOU HAVE TO ENJOY IT
Li, Zigang
李子刚
Pingshan Translational Medicine Center
PTMC Executive Director ,Senior Principal Investigator
lizg@szbl.ac.cn
Home page of research group:http://web.pkusz.edu.cn/li
Timeline
-
2019 - Present
Shenzhen Bay Laboratory Senior Principal Investigator
-
2010 - Present
Peking University Shenzhen Graduate School PI and Professor
-
2009 - 2010
Harvard University Postdoctoral Fellow
-
2004 - 2008
University of Chicago PhD
-
2001 - 2004
Tulane University MSc
-
1996 - 2001
University of Science and Technology of China BSc
Research Areas
The research team fuscous on the intersection of chemistry and biology to solve biological problems with chemical methods. The research areas include peptide engineering,microbial research, the methodology construction for secondary structure of stable peptides, the development of peptide drugs for important human diseases and antiviral peptides applications.
Highlights
Dr. Zigang Li, graduated from the University of Science and Technology of China with the bachelor degree in 2001, received the Ph.D. degree in Chemistry from the University of Chicago in 2008, and the postdoctoral degree in Chemistry and Chemical Biology from Harvard University in 2010. He returned to China in 2010 and was awarded the title of Distinguished Researchers in the "Hundred Talents Program" of Peking University. He is currently a doctoral supervisor and project leader of the chemical genomics major of Peking University. The research team focuses on the intersection of chemistry and biology to solve biological problems with chemical methods. The research team fuscous on the intersection of chemistry and biology to solve biological problems with chemical methods. The research areas include peptide engineering,microbial research, the methodology construction for secondary structure of stable peptides, the development of peptide drugs for important human diseases and antiviral peptides applications. In recent years, Dr Li has been published more than 80 papers in "Science Advances", "Nature Chemical Biology", "Cell Chemical Biology", "Proc. Natl. Acad. Sci.", "J. Am. Chem. Soc.", "Angew. Chem. Int. Ed. ","J. Med. Chem.", "Chemical Science", "Cancer research", "Chemical Reviews" and other top journals. He also has applied for more than 30 domestic patents and 3 PCT, and has carried out a number of international cooperation with Pfizer, Bayer Healthcare, Roche China and other multinational pharmaceutical companies.
Schematic presentation of biomimetic group transfer reaction for protein degradation. In this approach, the Osimertinib binds to the EGFR with high affinity, driving a group transfer reaction of the warhead with Cys located on the EGFR kinase pocket through the proximity effect. Different complicate groups were transferrable and showed proof-of-concept application in protein labelling, protein profiling and targeted protein degradation.
Inhibition of the interaction between p53 and MDM2/MDMX has attracted significant attention in anticancer therapy development. We designed a series of in-tether chiral center-induced helical stabilized peptides, among which MeR/PhR effectively reactivated p53. The activation of p53 inhibits cell proliferation and induces apoptosis in both the MCF-7 normal tumor cell line and the PA-1 pluripotent cancer cell line with only minimal cellular toxicity towards normal cells or cancer cell lines with p53 mutations. The in vivo bioactivity study of the peptide in the ovarian teratocarcinoma (PA-1) xenograft model showed a tumor growth rate inhibition of 70% with a dosage of 10 mg/kg (one injection every other day). This is the first application of a stabilized peptide modulator targeting stem-like cancer cell both in vitro and in vivo and provides references to cancer stem cell therapy.
Honors
• 2018 Second Prize of Shenzhen Science and Technology Progress Award
• 2016 Ten million leading talents of Guangdong special support plan
• 2013 Chutian Scholar Chair Professor, Hubei Province
• 2013 Shenzhen Outstanding Youth Funding
• 2013 Special Commissioner of Guangdong Science and Technology Enterprise
• 2012 Shenzhen Overseas High-level Talents
• 2011 Shenzhen High-level Talents
• 2010 Peking University Hundred Talents Program
• 2009-2010 American Cancer Center Postdoctoral Scholarship
• 2008-2009 University of Chicago Hubble Doctoral Dissertation Scholarship
Selected Publications
[1] F. Yang, Q. Luo, Y. Wang, H. Liang, Y. Wang, Z. Hou, C. Wan, Y. Wang, Z. Liu, Y. Ye, L. Zhu, J. Wu, F. Yin, Z. Li, J. Am. Chem. Soc. 2023, 145, 7879-7887.
[2] Y. Zhang, H. Xu, L. Jiang, Z. Liu, C. Lian, X. Ding, C. Wan, N. Liu, Y. Wang, Z. Yu, L. Zhu, F. Yin, Z. Li, ACS Nano. 2022, 16, 19509–19522.
[3] Y. Wang, R. Zhao, C. Wan, W. Kang, R. Wang, C. Chiang, X. Guo, Q. Chang, Z. Hou, Y. Ye, Q. Luo, Z. Zhou, J. Liu, S. Li, D. Wang, F. Yin, Z. Li, CCS Chem., 2022.
[4] X. Qin, R. Wang, H. Xu, L. Tu, H. Chen, H. Li, N. Liu, J. Wang, S. Li, F. Yin, N. Xu, Z. Li, Autophagy, 2022, 18, 2178-2197.
[5] Y. Jiang, W. Zhang, F. Yang, C. Wan, X. Cai, J. Liu, Q. Zhang, Z. Li, W. Han, Sci. Adv. 2021, 7, eabd0492.
[6] D. Wang, M. Yu, N. Liu, C. Lian, Z. Hou, R. Wang, R. Zhao, W. Li, Y. Jiang, X. Shi, S. Li, F. Yin, Z. Li, Chem. Sci. 2019, 10, 4966-4972.
[7] D. Wang, W. Li, R. Zhao, L. Chen, N. Liu, Y. Tian, H. Zhao, M. Xie, F. Lu, Q. Fang, W. Liang, F. Yin, Z. Li, Cancer Res. 2019, 79, 1769-1783.
[8] K. Hu, Y. Jiang, W. Xiong, H. Li, P. Zhang, F. Yin, Q. Zhang, H. Geng, F. Jiang, Z. Li, X. Wang, Z. Li, Sci. Adv. 2018,4, eaar5907.
[9] H. Zhao, Q. Liu, H. Geng, Y. Tian, M. Cheng, Y. Jiang, M. Xie, X. Niu, F. Jiang, Y. Zhang, Y. Lao, Y. Wu, N. Xu, Z. Li, Angew. Chem. Int. Ed. 2016, 55, 12088-12093.
[10] K. Hu, H. Geng, Q. Zhang, Q. Liu, M. Xie, C. Sun, W. Li, H. Lin, F. Jiang, T. Wang, Y. D. Wu, Z. Li, Angew. Chem. Int. Ed. 2016, 55, 8013-8017.